MENU
+Compare
URGN
Stock ticker: NASDAQ
AS OF
Jun 5, 04:59 PM (EDT)
Price
$5.14
Change
+$0.22 (+4.47%)
Capitalization
236.99M

URGN UroGen Pharma Ltd Forecast, Technical & Fundamental Analysis

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers... Show more

Industry: #Biotechnology
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for URGN with price predictions
Jun 04, 2025

URGN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on May 21, 2025

URGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 43 cases where URGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where URGN's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where URGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where URGN advanced for three days, in of 259 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on URGN as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for URGN turned negative on May 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

URGN moved below its 50-day moving average on May 13, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for URGN crossed bearishly below the 50-day moving average on May 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where URGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for URGN entered a downward trend on June 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.234) is normal, around the industry mean (16.306). P/E Ratio (0.000) is within average values for comparable stocks, (59.921). URGN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (2.544) is also within normal values, averaging (265.014).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. URGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. URGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

URGN is expected to report earnings to fall 11.40% to -81 cents per share on August 19

UroGen Pharma Ltd URGN Stock Earnings Reports
Q2'25
Est.
$-0.82
Q1'25
Missed
by $0.13
Q4'24
Missed
by $0.03
Q3'24
Beat
by $0.27
Q2'24
Missed
by $0.08
The last earnings report on May 12 showed earnings per share of -92 cents, missing the estimate of -79 cents. With 1.48M shares outstanding, the current market capitalization sits at 236.99M.
A.I. Advisor
published General Information

General Information

a developer of therapies for urological pathologies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
400 Alexander Park Drive
Phone
+1 646 768-9780
Employees
201
Web
https://www.urogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TBWIX21.090.18
+0.86%
Thornburg Better World International I
JGMAX24.360.06
+0.25%
Janus Henderson Triton A
KGDZX30.66N/A
N/A
DWS Global Small Cap R6
WSMRX25.47N/A
N/A
William Blair Small-Mid Cap Growth R6
LHCTX18.26N/A
N/A
Lord Abbett Health Care R5

URGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with CYYNF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then CYYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
-1.60%
CYYNF - URGN
38%
Loosely correlated
N/A
IDYA - URGN
35%
Loosely correlated
-2.50%
XNCR - URGN
33%
Loosely correlated
-0.44%
RVMD - URGN
33%
Loosely correlated
-0.49%
ACLX - URGN
33%
Loosely correlated
+0.52%
More